Do Not Split Entresto 24/26 mg Tablets
Entresto tablets should not be split. The FDA-approved drug label explicitly describes Entresto 24/26 mg as "unscored" tablets, which is a clear pharmaceutical indication that the medication is not designed or approved for splitting 1.
Why Tablet Splitting is Not Recommended for Entresto
Pharmaceutical Design Issues
- Unscored formulation: All three strengths of Entresto (24/26 mg, 49/51 mg, and 97/103 mg) are manufactured as unscored, ovaloid, film-coated tablets 1
- The absence of a score line is intentional—it signals that the manufacturer has not validated the drug for splitting
- Film-coated tablets are particularly problematic for splitting as the coating serves specific purposes (stability, absorption kinetics) that are disrupted when cut
Dose Accuracy Concerns
The 24/26 mg strength already represents the lowest available dose of Entresto, containing just 24 mg sacubitril and 26 mg valsartan 1. Attempting to split this would theoretically yield approximately 12 mg/13 mg doses, which:
- Falls below any studied or approved dosing regimen
- Has no evidence base for efficacy or safety
- Would likely result in subtherapeutic dosing
Research on tablet splitting demonstrates significant problems with dose uniformity, particularly for small tablets. Studies show that 15-16% of half-tablets fall outside acceptable weight and content specifications, with fragment loss during splitting being a major contributor 2.
Proper Dosing Strategy Instead
For Patients Requiring Lower Initial Doses
If the 24/26 mg tablet is still too high for initiation, the FDA label provides a specific alternative 1:
- Use the oral suspension formulation prepared from the 49/51 mg tablets
- This allows precise dose titration, particularly for:
- Pediatric patients requiring weight-based dosing (0.8 mg/kg twice daily)
- Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²)
- Patients with moderate hepatic impairment (Child-Pugh B)
- Patients not previously on ACE inhibitors or ARBs
Titration Approach
The 2022 AHA/ACC/HFSA guidelines emphasize that titration to target doses is critical for reducing cardiovascular mortality and heart failure hospitalizations 3. The evidence shows:
- The 24/26 mg dose is associated with significantly higher mortality and hospitalization rates compared to higher doses 4
- Patients on 24/26 mg had 29% HF hospitalization rates vs. 16% on 97/103 mg (HR 1.79,95% CI 1.18-2.73)
- All-cause mortality was 30% on 24/26 mg vs. 9% on 97/103 mg (HR 2.56,95% CI 1.54-4.24)
The goal should be rapid uptitration to the target dose of 97/103 mg twice daily, not dose reduction below the lowest available strength 3.
Common Pitfalls to Avoid
- Do not split tablets to save costs—this compromises efficacy and patient outcomes
- Do not remain on 24/26 mg long-term—this is a starting dose, not a maintenance dose
- Do not skip the washout period: Allow 36 hours when switching from ACE inhibitors to avoid angioedema risk 1
- Titrate every 1-2 weeks in adults (every 2 weeks in pediatrics) as tolerated, monitoring blood pressure, renal function, and potassium 3
If a patient cannot tolerate uptitration due to hypotension or other adverse effects, address the underlying cause (volume depletion, medication timing, concomitant medications) rather than resorting to tablet splitting.